Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KJ-01
- Development stage
- Preclinical
- Lead developer
- Kiji Therapeutics
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
KJ-01 is a gene-engineered, donor-derived adipose mesenchymal stem cell (Ad-MSC) therapy being developed by REGiMMUNE/Kiji TX (formed by the merger of REGiMMUNE and Kiji Therapeutics) for the treatment of steroid-refractory graft-versus-host disease (SR-GvHD). The cells are transduced with a lentiviral vector to express interleukin-10 (IL-10) and C-X-C chemokine receptor type 4 (CXCR4). IL-10 provides localized immunomodulatory activity to suppress inflammation, while CXCR4 enhances the homing of the therapeutic cells to sites of active disease. KJ-01 is currently in IND-enabling development, with clinical entry planned.
- Other names
- KJ01KJ-01KJ 01
02
Targets
CXCR7 (CXC chemokine receptor 7)CXCL12 (C-X-C motif chemokine ligand 12)CXCR4 (C-X-C motif chemokine receptor 4)IL10 (Interleukin-10)
Beyond the preview
Go deeper on KJ-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KJ-01.